Vaxneuvance Market Growth Patterns And Forecast Outlook Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Vaxneuvance Market Be By 2030 Compared To Its 2026 Market Size?

The historical growth can be attributed to the widespread implementation of routine pneumococcal immunization programs, an increased occurrence of pneumococcal infections, enhanced public understanding of vaccine-preventable conditions, advancements in conjugate vaccine technology, and improved accessibility to healthcare services.

The expansion observed in the forecast period can be attributed to increased investments in pioneering vaccines, a heightened focus on immunizing older adults, the broadening of national vaccination initiatives, an escalating demand for vaccines offering broader protection, and their growing integration into developing healthcare systems. Prominent trends throughout this period include the rising adoption of broad-spectrum pneumococcal vaccines, an intensified effort towards preventing invasive diseases, expanding immunization coverage for both children and adults, advancements and wider application of conjugate vaccine technologies, and an elevated emphasis on safeguarding high-risk populations.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20428&type=smp

Which Important Drivers Are Guiding The Vaxneuvance Market Growth?

The vaxneuvance market is projected to expand due to the widespread occurrence of pneumonia. This condition involves inflammation of the lung’s air sacs, which can become filled with fluid or pus, leading to symptoms like coughing, fever, and difficulty breathing. Its widespread occurrence stems from various factors, including viral and bacterial infections, compromised immune systems, environmental air pollution, and a growing elderly population more vulnerable to respiratory ailments. Vaxneuvance offers protection to individuals by targeting pneumonia caused by 15 specific strains of Streptococcus pneumoniae, thereby mitigating the chances of severe infections and associated health issues. An illustration of this trend is seen in 2024, when the Johns Hopkins University, a US-based research university, reported that the average Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries reached 56%, marking a 2% rise from 54% in 2023. Consequently, the substantial presence of pneumonia is propelling the expansion of the vaxneuvance market.

How Is Segmentation Applied In The Vaxneuvance Market Segment Analysis?

The vaxneuvance market covered in this report is segmented –

1) By Indication: Pneumonia, Meningitis, Sepsis, Bacteremia, Otitis Media

2) By Distribution Channel: Pharmacies, Hospitals

3) By End User: Adults, Children, Geriatric Population

Which Trends Are Guiding The Direction Of The Vaxneuvance Market?

Major companies operating in the vaxneuvance (pneumococcal conjugate vaccine) market are focusing on developing innovative solutions, such as next-generation multivalent conjugate vaccines, to provide broader protection against pneumococcal infections. These next-generation multivalent conjugate vaccines are advanced vaccines designed to protect against multiple strains of a pathogen by linking polysaccharides from each strain to a carrier protein, thereby enhancing the immune response. For instance, in May 2025, Vietnam Vaccine JSC (VNVC), a US-based company, introduced the pneumococcal 15-valent conjugate vaccine (PCV15 or Vaxneuvance) to expand protection against multiple strains of Streptococcus pneumoniae responsible for invasive and non-invasive diseases. The vaccine targets children from six weeks of age as well as adults, offering long-lasting immunity and helping reduce the transmission of pneumococcal bacteria within the community. This launch positions VNVC at the forefront of modern pneumococcal vaccination in Vietnam, complementing its existing portfolio of pneumococcal vaccines and strengthening national immunization efforts.

Who Are The Companies Participating In The Vaxneuvance Market Environment?

Major companies operating in the vaxneuvance market are Merck & Co. Inc.

Get The Full Vaxneuvance Market Report:

https://www.thebusinessresearchcompany.com/report/vaxneuvance-global-market-report

Which Region Represents The Largest Share Of The Vaxneuvance Market?

North America was the largest region in the vaxneuvance market in 2025. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Vaxneuvance Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/vaxneuvance-global-market-report

Browse Through More Reports Similar to the Global Vaxneuvance Market 2026, By The Business Research Company

Vat Dyes Market Report 2026

https://www.thebusinessresearchcompany.com/report/vat-dyes-global-market-report

Video As A Service Vaas Market Report 2026

https://www.thebusinessresearchcompany.com/report/video-as-a-service-vaas-global-market-report

Vaccine Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795